RG Shanks

695 total citations
39 papers, 592 citations indexed

About

RG Shanks is a scholar working on Analytical Chemistry, Pharmacology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, RG Shanks has authored 39 papers receiving a total of 592 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Analytical Chemistry, 14 papers in Pharmacology and 13 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in RG Shanks's work include Analytical Methods in Pharmaceuticals (15 papers), Pharmacological Effects and Assays (9 papers) and Pharmacology and Obesity Treatment (8 papers). RG Shanks is often cited by papers focused on Analytical Methods in Pharmaceuticals (15 papers), Pharmacological Effects and Assays (9 papers) and Pharmacology and Obesity Treatment (8 papers). RG Shanks collaborates with scholars based in United Kingdom, Ireland and United States. RG Shanks's co-authors include J.G. Kelly, N P Campbell, D. W. G. Harron, DG McDevitt, DP Nicholls, GD Johnston, T H Pringle, Richard Wilson, DG McDevitt and D. Arndts and has published in prestigious journals such as British Journal of Clinical Pharmacology and PubMed.

In The Last Decade

RG Shanks

37 papers receiving 489 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
RG Shanks United Kingdom 12 243 146 124 106 78 39 592
PA Meredith United Kingdom 14 315 1.3× 158 1.1× 121 1.0× 86 0.8× 69 0.9× 33 646
Peter C. Rubin United Kingdom 16 258 1.1× 115 0.8× 94 0.8× 68 0.6× 61 0.8× 48 868
HL Elliott United Kingdom 17 381 1.6× 197 1.3× 186 1.5× 126 1.2× 105 1.3× 57 876
Sandra R. Harapat United States 16 258 1.1× 215 1.5× 115 0.9× 170 1.6× 101 1.3× 18 862
Chii‐Ming Lai United States 14 147 0.6× 106 0.7× 99 0.8× 107 1.0× 116 1.5× 36 660
T E Gaffney United States 14 203 0.8× 52 0.4× 125 1.0× 73 0.7× 70 0.9× 32 722
G. Cuisinaud France 14 152 0.6× 74 0.5× 110 0.9× 161 1.5× 53 0.7× 46 608
Richard A. Okerholm United States 18 131 0.5× 129 0.9× 163 1.3× 170 1.6× 193 2.5× 36 842
W. Dieterle Switzerland 18 181 0.7× 145 1.0× 170 1.4× 171 1.6× 182 2.3× 50 877
Gwyn H. Evans United States 11 180 0.7× 174 1.2× 160 1.3× 205 1.9× 226 2.9× 12 921

Countries citing papers authored by RG Shanks

Since Specialization
Citations

This map shows the geographic impact of RG Shanks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by RG Shanks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites RG Shanks more than expected).

Fields of papers citing papers by RG Shanks

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by RG Shanks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by RG Shanks. The network helps show where RG Shanks may publish in the future.

Co-authorship network of co-authors of RG Shanks

This figure shows the co-authorship network connecting the top 25 collaborators of RG Shanks. A scholar is included among the top collaborators of RG Shanks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with RG Shanks. RG Shanks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shanks, RG, et al.. (1992). Dose‐dependent alpha 1‐adrenoceptor antagonist activity of the anti‐ arrhythmic drug, abanoquil (UK‐52,046), without reduction in blood pressure in man.. British Journal of Clinical Pharmacology. 33(4). 405–409. 1 indexed citations
2.
Shanks, RG, et al.. (1991). Cardiovascular effects of cromakalim (BRL 34915) in healthy volunteers.. British Journal of Clinical Pharmacology. 32(1). 45–49. 16 indexed citations
3.
Krawiec, Donald R., et al.. (1989). Nephrotoxicity of amphotericin B in dogs: a comparison of two methods of administration.. PubMed. 53(1). 23–8. 16 indexed citations
4.
Nicholls, DP, et al.. (1989). The pharmacokinetics of xamoterol in liver disease.. British Journal of Clinical Pharmacology. 28(6). 718–721. 2 indexed citations
5.
Harron, D. W. G., et al.. (1989). Effect of the combination of alinidine and other anti‐anginal drugs on heart rate and blood pressure in healthy volunteers.. British Journal of Clinical Pharmacology. 27(1). 23–29. 5 indexed citations
6.
Harron, D. W. G., et al.. (1988). Effect of acute and chronic oral administration of alfuzosin on baroreflex function and tremor in man.. British Journal of Clinical Pharmacology. 25(4). 417–424. 6 indexed citations
7.
Shanks, RG, et al.. (1987). An assessment of the partial agonist activity of Ro 31‐1118, flusoxolol and pindolol in man.. British Journal of Clinical Pharmacology. 24(5). 571–580. 17 indexed citations
8.
Pringle, T H, et al.. (1987). The assessment in man of the beta‐adrenoceptor blocking activity and cardioselectivity of H‐I 42 BS, a long acting beta‐adrenoceptor blocking drug.. British Journal of Clinical Pharmacology. 23(4). 411–423. 1 indexed citations
9.
Pringle, T H, et al.. (1986). Pharmacodynamic and pharmacokinetic studies on bufuralol in man.. British Journal of Clinical Pharmacology. 22(5). 527–534. 8 indexed citations
10.
Meredith, PA, et al.. (1985). Comparison of the haemodynamic effects of bucindolol, propranolol and pindolol in healthy volunteers.. British Journal of Clinical Pharmacology. 20(6). 659–667. 7 indexed citations
11.
Nicholls, DP, et al.. (1984). Effect of indoramin, labetalol and alinidine on sympathetic function in normal man.. British Journal of Clinical Pharmacology. 18(2). 215–221. 9 indexed citations
12.
Nicholls, DP, et al.. (1984). Differential blockade of alpha‐adrenoceptors by indoramin.. British Journal of Clinical Pharmacology. 17(6). 719–728. 10 indexed citations
13.
Shanks, RG, et al.. (1983). Comparison of the effect of pindolol and propranolol on heart rate after acute and chronic administration.. British Journal of Clinical Pharmacology. 15(4). 431–434. 4 indexed citations
14.
Harron, D. W. G., D. Arndts, & RG Shanks. (1982). Alinidine pharmacokinetics following acute and chronic dosing.. British Journal of Clinical Pharmacology. 13(6). 821–827. 11 indexed citations
15.
Shanks, RG, et al.. (1981). Comparison of the beta‐adrenoceptor blocking activity of oxprenolol, slow release oxprenolol and a combined oxprenolol diuretic preparation.. British Journal of Clinical Pharmacology. 12(6). 869–871. 5 indexed citations
16.
Wilson, Richard, et al.. (1981). Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta‐adrenoceptor blocking drug.. British Journal of Clinical Pharmacology. 11(2). 171–180. 29 indexed citations
17.
Shanks, RG, et al.. (1980). Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol.. British Journal of Clinical Pharmacology. 9(1). 33–40. 57 indexed citations
18.
Shanks, RG. (1978). Clinical pharmacology methodology: introduction.. British Journal of Clinical Pharmacology. 6(1). 5–6. 4 indexed citations
19.
Campbell, N P, et al.. (1978). The clinical pharmacology of mexiletine.. British Journal of Clinical Pharmacology. 6(2). 103–108. 104 indexed citations
20.
Shanks, RG, et al.. (1977). Evaluation of once daily sotalol administration in man.. British Journal of Clinical Pharmacology. 4(2). 153–156. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by PA Meredith Breakdown of academic impact, for papers by Peter C. Rubin Breakdown of academic impact, for papers by HL Elliott Breakdown of academic impact, for papers by Sandra R. Harapat Breakdown of academic impact, for papers by Chii‐Ming Lai Breakdown of academic impact, for papers by T E Gaffney Breakdown of academic impact, for papers by G. Cuisinaud Breakdown of academic impact, for papers by Richard A. Okerholm Breakdown of academic impact, for papers by W. Dieterle Breakdown of academic impact, for papers by Gwyn H. Evans
Rankless by CCL
2026